Core Viewpoint - enVVeno Medical Corporation is setting new standards of care for the treatment of deep venous disease, as highlighted by CEO Robert Berman's participation in a Virtual Investor segment [1] Company Overview - enVVeno Medical Corporation is publicly traded on NASDAQ under the ticker NVNO [1] - The company focuses on innovative treatments for deep venous disease [1] Leadership Insight - CEO Robert Berman's involvement in the Virtual Investor segment emphasizes the company's commitment to engaging with investors and communicating its vision [1]

Core Viewpoint - enVVeno Medical Corporation is seeking to appeal the not-approvable letter from the FDA regarding its VenoValve® device for treating severe deep chronic venous insufficiency [1] Group 1: Company Actions - The company plans to file a request for a supervisory appeal to challenge the FDA's decision received on August 19, 2025 [1] - The appeal will utilize the FDA's internal mechanisms to contest the review staff's decision, which may involve scientific controversies [1] Group 2: Product Information - The VenoValve® is a surgical replacement venous valve designed for the treatment of severe deep chronic venous insufficiency (CVI) [1]

Core Insights - Shares of enVVeno Medical (NVNO) have experienced a significant decline of 76.1% since August 19 due to the FDA's not-approvable letter regarding its Premarket Approval (PMA) application for the VenoValve [1][8] Company Overview - enVVeno Medical submitted the PMA application for VenoValve, intended as a surgical replacement venous valve for severe chronic venous insufficiency (CVI), based on data from the successful SAVVE trial [2] - The FDA found the trial data insufficient to assess the benefit-to-risk profile of VenoValve, which is the company's most advanced pipeline candidate [3][9] Price Performance - Year-to-date, NVNO shares have declined by 66.9%, significantly underperforming the industry, which has seen a decline of 6.7%, while the S&P 500 Index has increased by 9.8% [4] Financial Outlook - The company has a cash burn rate of $4-$5 million per quarter, which is expected to sustain operations through Q3 2026, including activities related to VenoValve and another candidate, enVVe [5] - The FDA's decision is likely to delay VenoValve's commercialization, impacting NVNO's revenue generation potential [5] FDA's Denial Details - The FDA's not-approvable letter cited insufficient data from the SAVVE study and raised concerns about surgical safety, particularly regarding re-hospitalizations associated with the VenoValve procedure [8][10] - The FDA noted that clinical improvements observed may not correlate with the benefit-to-risk profile due to the lack of specific hemodynamic measurements [9][10] Future Steps - enVVeno Medical is reviewing FDA feedback and may seek a meeting to discuss potential resubmission or appeal regarding VenoValve [11] - The company is also advancing the enVVe valve, a non-surgical option, and plans to submit an IDE filing for its pivotal trial soon, which could positively impact NVNO's share price [12]

Financial Performance - The company reported a net loss of $6.7 million for the three months ended June 30, 2025, compared to a net loss of $5.0 million for the same period in 2024, representing a 35% increase in net loss [55]. - Net losses for the six months ended June 30, 2025, were $11.2 million, an increase of $1.2 million or 13% compared to $10.0 million for the same period in 2024 [60]. - The company incurred losses from operations of $12.0 million and used $7.7 million in cash for operating activities for the six months ended June 30, 2025 [65]. - Other income for the six months ended June 30, 2025, decreased by $0.2 million to $0.8 million from $1.0 million for the same period in 2024 [64]. - Selling, general and administrative expenses for the three months ended June 30, 2025, increased by $1.6 million or 58%, to $4.2 million from $2.6 million for the same period in 2024 [58]. - Selling, general and administrative expenses for the six months ended June 30, 2025, increased by $1.5 million or 29%, to $6.6 million from $5.1 million for the same period in 2024 [63]. - Research and development expenses for the three months ended June 30, 2025, increased by $0.1 million or 2%, to $2.9 million from $2.8 million for the same period in 2024 [57]. - Research and development expenses for the six months ended June 30, 2025, decreased by $0.5 million or 7%, to $5.4 million from $5.9 million for the same period in 2024 [62]. - The anticipated cash burn rate is expected to increase to between $5 million and $7 million per quarter as the company conducts clinical studies and works toward product commercialization [69]. - The company expects to file for IDE approval for the enVVe pivotal study in the third quarter of 2025, following successful completion of pre-clinical testing [53]. - The company has sufficient capital resources to meet obligations for at least one year after June 30, 2025 [70]. - The company does not expect to generate significant revenue until successful commercialization of its product candidates after receiving FDA approval [61]. Product Development - The VenoValve is currently in the post-enrollment follow-up period of its U.S. pivotal study, which reached full enrollment of 75 patients on September 1, 2023 [46]. - At one year follow-up, 85% of patients in the VenoValve trial experienced a clinically meaningful benefit, with an average improvement of 7.91 points in the revised Venous Clinical Severity Score (rVCSS) [48]. - The median reduction in pain for patients in the VenoValve study was 75%, and for CEAP C6 patients, ulcer area was reduced by a median of 87% [48]. - The VenoValve has been granted Breakthrough Device designation by the FDA, which may expedite its PMA review process [45][50]. - The company is developing the enVVe as a next-generation, non-surgical replacement venous valve, currently undergoing pre-clinical testing [37][52]. Market Context - Approximately 20 million people in the U.S. are estimated to suffer from severe deep venous CVI (C4 to C6 disease), with 3.5 million new cases diagnosed annually [44]. - The average annual cost for a patient seeking treatment for a venous ulcer is estimated to be $30,000, with total direct medical costs exceeding $3 billion annually in the U.S. [44].

Financial Performance - The company reported net losses of $4.5 million for Q1 2025, a decrease of 10% from $5.0 million in Q1 2024[56]. - Other income decreased by $0.1 million or 25% to $0.4 million for the three months ended March 31, 2025, compared to $0.5 million for the same period in 2024[60]. - The company incurred losses from operations of $5.0 million and used $4.0 million in operating activities for the three months ended March 31, 2025, an increase of $0.4 million from $3.6 million in the same quarter of 2024[61]. - The increase in cash usage is primarily due to product research and development activities, including clinical studies for VenoValve and enVVe[62]. - The company does not currently generate revenue and does not expect significant revenue until successful commercialization of product candidates after FDA approval[63]. Research and Development - Research and development expenses decreased by $0.5 million or 19% to $2.6 million in Q1 2025, primarily due to lower costs related to the VenoValve pivotal study[58]. - The VenoValve pivotal study reached full enrollment on September 1, 2023, and is currently in the post-enrollment follow-up period[47]. - The company expects to file for IDE approval for the enVVe pivotal study in Q3 2025[54]. - The VenoValve has shown an 85% clinical meaningful benefit at one year, with an average improvement of 7.91 points in the revised Venous Clinical Severity Score (rVCSS)[50]. - The VenoValve is estimated to be eligible for FDA approval in the second half of 2025[51]. - The increase in cash usage is primarily due to product research and development activities, including clinical studies for VenoValve and enVVe[62]. Financial Position and Capital Requirements - The company finished 2024 with approximately $43.2 million in cash and investments, with an expected increase in cash burn rate to $4 million to $5 million per quarter[55]. - Future capital requirements will depend on the success of clinical studies and product development costs, with an anticipated cash burn rate increasing to $5 million per quarter[65]. - The company has sufficient capital resources to meet obligations for at least one year after March 31, 2025, based on current cash and working capital[66]. - The company expects a modest increase in property and equipment purchases as it continues clinical studies and plans for commercialization of VenoValve[64]. Market Context - The total direct medical costs from venous ulcer sufferers in the U.S. exceed $3 billion annually[45]. - Approximately 20 million people in the U.S. are estimated to suffer from severe deep venous CVI (C4 to C6 disease) with reflux[45].

Financial Performance - The company reported net losses of $21.8 million for the year ended December 31, 2024, a decrease of 7% from the $23.5 million loss in 2023[173]. - The company incurred losses from operations of $23.8 million and used $16.8 million in cash for operating activities in 2024, a decrease from $18.9 million in 2023[179]. - The cash balance as of December 31, 2024, was $1.8 million, with total cash and investments amounting to $43.2 million[179]. - The company anticipates an increase in cash burn rate to $5 million to $6 million per quarter in 2025, while having sufficient cash to fund operations through mid-2026[183]. Expenses - Research and development expenses decreased by 10% to $12.2 million in 2024 from $13.6 million in 2023, primarily due to reduced costs for the SAVVE trial[174]. - Selling, general and administrative expenses decreased by 1% to $11.6 million in 2024, driven by a $1.1 million reduction in share-based compensation[176]. Income and Investments - Other income increased to $2.0 million in 2024 from $1.7 million in 2023, reflecting realized gains and interest from investments in U.S. Treasury securities[178]. - The company has no current revenue and relies on future commercialization of its products for potential income[172]. Future Plans - The company aims to receive FDA approval for the VenoValve in 2026 and has begun limited activities toward commercial launch[181]. - The company expects a modest increase in capital expenditures related to ongoing clinical trials and commercialization efforts[182].

Core Insights - enVVeno Medical's submission of the final module for VenoValve's Premarket Approval (PMA) application to the FDA is a significant milestone in addressing the treatment of Chronic Venous Insufficiency (CVI) [1][4] - The device targets a market of approximately 2.5 million candidates annually in the U.S., positioning enVVeno to potentially transform the standard of care for venous disease [2] - Despite a recent 5.5% drop in share price to $3.41, the latest development is expected to positively influence market sentiment towards NVNO stock [3][4] Company Developments - The latest submission is the fifth and final module of the FDA application, containing favorable clinical data, following the approval of the previous four modules [4] - NVNO's market capitalization stands at $59.8 million, with an estimated earnings growth of 31.9% projected for 2024 [5] - VenoValve's PMA approval could significantly expand enVVeno's portfolio of bioprosthetic solutions, aligning with the company's mission to develop innovative treatments for venous disease [6][8] Market Potential - The global venous disease treatment market was valued at $6.17 billion in 2023 and is projected to reach $10.85 billion by 2031, growing at a CAGR of 7.30% [9] - The market expansion is driven by the rising prevalence of diabetes and advancements in technology, indicating a favorable environment for enVVeno's growth [9] Competitive Position - VenoValve's pending approval is expected to catalyze enVVeno's growth in the medical device market, fostering new revenue streams and enhancing its competitive position [7] - The planned pivotal trial for the enVVe valve in mid-2025 further emphasizes enVVeno's focus on innovation and market expansion [7]

Clinical Trials and Device Development - The VenoValve is currently being evaluated in the SAVVE trial, with definitive one-year data expected in Q4 2024[33]. - The SAVVE trial achieved full enrollment of 75 subjects on September 1, 2023, across 21 U.S. sites[46]. - Preliminary data from the SAVVE study indicated an 8% rate of device-related material adverse events (MAEs) among the 75 subjects, with no deaths reported[48]. - At six months, 97% of patients showed clinical improvement as measured by the revised Venous Clinical Severity Score (rVCSS), with 74% achieving a clinically meaningful benefit[49]. - The average improvement in rVCSS among the clinically meaningful benefit cohort was 8 points, significantly exceeding the required improvement[50]. - For venous ulcer patients in the SAVVE study, 91% showed healing or improvement at one year, with 100% of ulcers lasting one year or less fully healed[51]. - The company expects to file the final module of its premarket approval (PMA) application for the VenoValve in Q4 2024, having already filed four of the five required modules[52]. - The enVVe valve is being developed for non-surgical treatment of CVI, targeting an estimated market of 3.5 million patients in the U.S.[53]. - The company is conducting pre-clinical testing on enVVe, with plans to file for IDE approval for its pivotal trial in mid-2025[34]. - The company plans to file for IDE approval for the enVVe pivotal study in mid-2025, following the completion of a six-month pre-clinical GLP study[54]. Financial Performance - The company reported a net loss of $5.6 million for the three months ended September 30, 2024, an increase of 12% compared to a net loss of $5.0 million for the same period in 2023[59]. - Research and development expenses for the three months ended September 30, 2024, increased by 2% to $2.9 million from $2.8 million in the prior year[60]. - Selling, general and administrative expenses rose by 27% to $3.3 million for the three months ended September 30, 2024, compared to $2.6 million in the same period in 2023[60]. - The company closed a public offering on September 30, 2024, raising approximately $13.6 million in net cash proceeds, which is expected to fund operations through significant milestones[57]. - As of September 30, 2024, the company had approximately $48.4 million in cash and investments, up from $46.4 million at the end of 2023[55]. - The anticipated cash burn rate is expected to increase to $4 million to $5 million per quarter as clinical trials progress[56]. - For the nine months ended September 30, 2024, the company reported a net loss of $15.6 million, a decrease of 13% from a net loss of $17.9 million for the same period in 2023[61]. - Other income increased by 52% to $0.5 million for the three months ended September 30, 2024, compared to $0.3 million in the prior year[61]. - The company incurred $11.7 million in cash used in operating activities for the nine months ended September 30, 2024, a decrease of $2.2 million from $13.9 million in the same period in 2023[67].

Clinical Trials and Product Development - The VenoValve is currently being evaluated in the SAVVE trial, with patients reporting reduced pain and enhanced quality of life[26] - The company expects to file for FDA approval of the VenoValve in Q4 2024, followed by the enVVe in 2026[27] - The SAVVE trial achieved full enrollment of 75 subjects on September 1, 2023, four months earlier than expected due to increased demand[38] - Preliminary data from the SAVVE study indicated an 8% rate of device-related material adverse events within 30 days of enrollment[40] - At the six-month mark, 97% of patients showed clinical improvement as measured by rVCSS, with an average improvement of 8 points[41] - The VenoValve has been granted Breakthrough Device designation by the FDA, indicating its potential significance in treating severe CVI[34] - The company is also developing the enVVe, a non-surgical replacement venous valve system, with IDE approval expected in Q2 2025[26] - The average improvement in the Clinical Meaningful Benefit cohort was 8.46 points, with 94% of patients showing clinical improvement at a follow-up of 11.04 months[42] - In the SAVVE study, 91% of venous ulcer patients evaluated at one year either had fully healed ulcers or ulcers that had improved, with 100% of ulcers lasting one year or less fully healed[43] - The company expects to file the PMA application for the VenoValve in Q4 of 2024, pending one-year data for all 75 patients[44] - The enVVe system targets approximately 3.5 million patients in the U.S. market for the treatment of chronic venous insufficiency (CVI)[44] Financial Performance - Research and development expenses decreased by 33.3% to $2.8 million for the three months ended June 30, 2024, compared to $4.2 million for the same period in 2023[48] - The company reported net losses of $5.0 million for the three months ended June 30, 2024, a decrease of 23.1% from $6.5 million in the same period in 2023[46] - Selling, general and administrative expenses remained flat at $2.6 million for the three months ended June 30, 2024, compared to the same period in 2023[48] - The company incurred a net loss of $10.0 million for the six months ended June 30, 2024, a decrease of 22.5% from $12.9 million in the same period in 2023[51] - Cash burn rate is expected to increase from approximately $4 million to $5 million per quarter as clinical trials progress[55] - The company had approximately $39.1 million in cash and investments as of June 30, 2024[46] Market Impact and Patient Statistics - Approximately 20 million people in the U.S. suffer from severe deep venous CVI (C4 to C6 disease) with reflux[32] - The average annual treatment cost for a patient with a venous ulcer is estimated at $30,000, with total direct medical costs exceeding $3 billion annually in the U.S.[32] - Severe CVI patients miss approximately 40% more workdays than the average worker, highlighting the condition's impact on quality of life[31]

Clinical Trials and Device Development - The VenoValve is currently being evaluated in the SAVVE trial, with patients reporting reduced pain and enhanced quality of life[41] - The SAVVE trial achieved full enrollment of 75 subjects on September 1, 2023, four months earlier than expected due to increased demand[59] - Preliminary device-related adverse event data from the SAVVE study indicated an 8% rate of material adverse events within 30 days of enrollment[60] - At the six-month mark, 97% of patients in the SAVVE study showed clinical improvement as measured by rVCSS, with an average improvement of 8 points[61] - The VenoValve has been granted Breakthrough Device designation by the FDA, indicating its potential significance in treating severe CVI[51] - The VenoValve showed a clinical improvement in 94% of study patients, with an average improvement of 8.46 points in rVCSS[62] - The company expects to file the PMA application for the VenoValve in Q4 2024, pending one-year data for all 75 patients[63] - The company expects to file for IDE approval for the enVVe pivotal trial in Q2 of 2025[42] - The company plans to start a six-month chronic GLP study for the enVVe valve in Q3 2024, with IDE approval expected to be filed in Q2 2025[65] Market and Financial Overview - Approximately 20 million people in the U.S. are estimated to suffer from severe deep venous CVI (C4 to C6 disease) with reflux[50] - The average annual treatment cost for a patient with a venous ulcer is estimated at $30,000, with total direct medical costs exceeding $3 billion annually in the U.S.[50] - The enVVe system targets an estimated U.S. market of approximately 3.5 million patients with less severe CVI[64] - The company reported net losses of $5.0 million for Q1 2024, a decrease of 22% from $6.4 million in Q1 2023[67] - Research and development expenses decreased by 14% to $3.1 million in Q1 2024, down from $3.6 million in Q1 2023[69] - Selling, general and administrative expenses decreased by 22% to $2.5 million in Q1 2024, compared to $3.2 million in Q1 2023[70] - Other income increased by 25% to $0.5 million in Q1 2024, up from $0.4 million in Q1 2023[71] - The company finished 2023 with approximately $46.4 million in cash and investments, and had approximately $42.9 million as of March 31, 2024[66] - The company anticipates a cash burn rate increase from approximately $4 million to $5 million per quarter as clinical trials progress[75] Regulatory and Approval Timeline - The VenoValve is projected to be eligible for FDA approval in Q4 of 2024, with enVVe expected to follow two to three years later[44]